BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 25753965)

  • 21. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
    J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.
    Dridi NP; Johansson PI; Clemmensen P; Stissing T; Radu MD; Qayyum A; Pedersen F; Helqvist S; Saunamäki K; Kelbæk H; Jørgensen E; Engstrøm T; Holmvang L
    Platelets; 2014; 25(7):506-12. PubMed ID: 24245960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI.
    Yang TH; Jin HY; Choi KN; Do U; Kim HJ; Chung SR; Seo JS; Jang JS; Kim DK; Kim DS
    Int J Cardiol; 2013 Sep; 168(1):207-11. PubMed ID: 23106905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests.
    Woo KS; Kim BR; Kim JE; Goh RY; Yu LH; Kim MH; Han JY
    Korean J Lab Med; 2010 Oct; 30(5):460-8. PubMed ID: 20890076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
    Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
    Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of clopidogrel use post coronary artery bypass surgery on graft patency.
    Ebrahimi R; Bakaeen FG; Uberoi A; Ardehali A; Baltz JH; Hattler B; Almassi GH; Wagner TH; Collins JF; Grover FL; Shroyer AL
    Ann Thorac Surg; 2014 Jan; 97(1):15-21. PubMed ID: 24206971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting.
    Shennib H; Endo M; Benhameid O
    Heart Surg Forum; 2003; 6(5):288-91. PubMed ID: 14721795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting.
    Campo G; Valgimigli M; Carrescia C; Carletti R; Ferrari R
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):591-3. PubMed ID: 19520678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
    Baber U; Akhter M; Kothari S; Sharma SK; Kini A
    J Invasive Cardiol; 2010 Feb; 22(2):80-3. PubMed ID: 20124594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
    Breet NJ; van Werkum JW; Bouman HJ; Kelder JC; Harmsze AM; Hackeng CM; ten Berg JM
    Heart; 2011 Jun; 97(12):983-90. PubMed ID: 21478385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting.
    Gasparovic H; Petricevic M; Kopjar T; Djuric Z; Svetina L; Biocina B
    Am J Cardiol; 2014 May; 113(10):1660-7. PubMed ID: 24666617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.
    Panchal HB; Shah T; Patel P; Albalbissi K; Molnar J; Coffey B; Khosla S; Ramu V
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):533-43. PubMed ID: 23872509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy?
    Bagoly Z; Homoródi N; Kovács EG; Sarkady F; Csiba L; Édes I; Muszbek L
    Platelets; 2016; 27(1):59-65. PubMed ID: 26083485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of Different β-Blockers on Platelet Aggregation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy.
    Ignjatovic V; Pavlovic S; Miloradovic V; Andjelkovic N; Davidovic G; Djurdjevic P; Stolic R; Iric-Cupic V; Simic I; Ignjatovic VD; Petrovic N; Smiljanic Z; Zdravkovic V; Simovic S; Jovanovic D; Nesic J
    J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):44-52. PubMed ID: 25868659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention.
    Ha SJ; Kim SJ; Hwang SJ; Woo JS; Kim W; Kim WS; Kim KS; Kim MK
    Coron Artery Dis; 2013 Dec; 24(8):690-7. PubMed ID: 24152567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clopidogrel did not inhibit platelet function early after coronary bypass surgery: A prospective randomized trial.
    Lim E; Cornelissen J; Routledge T; Kirtland S; Charman SC; Bellm S; Munday H; Khan O; Masood I; Large S
    J Thorac Cardiovasc Surg; 2004 Sep; 128(3):432-5. PubMed ID: 15354104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
    Yong G; Rankin J; Ferguson L; Thom J; French J; Brieger D; Chew DP; Dick R; Eccleston D; Hockings B; Walters D; Whelan A; Eikelboom JW
    Am Heart J; 2009 Jan; 157(1):60.e1-9. PubMed ID: 19081397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
    Guthikonda S; Alviar CL; Vaduganathan M; Arikan M; Tellez A; DeLao T; Granada JF; Dong JF; Kleiman NS; Lev EI
    J Am Coll Cardiol; 2008 Aug; 52(9):743-9. PubMed ID: 18718422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.